The Bone and Soft-tissue Tumor Program at Arkansas Children’s Hospital provides specialty care for children with cancer of the bone, muscle, or connective tissues.
If your newborn or young child has been diagnosed with sickle cell disease, you likely have a lot of questions. The good news is, with the right care, many children with sickle cell live long, healthy lives. Arkansas Children's can diagnose, evaluate and treat children who have sickle cell disease.
When your child is diagnosed with hemophilia or a bleeding disorder, the experts at the Arkansas Center for Bleeding Disorders work with you and your child to create a care plan that keeps your child healthy while living life to the fullest.
The doctors and care teams at Arkansas Children's are highly skilled in the diagnosis, evaluation, and treatment of childhood problems related to blood and tumors.
Surround your child with experts who also care for the following conditions.
At Arkansas Children’s your child will have access to a wide range of treatments, from traditional to experimental.
As a respected leader in pediatric cancer treatment, Arkansas Children's is a member of several groups dedicated to improving the lives of children and families living with cancer and blood disorders. Membership in these groups lets your child receive cutting-edge treatments and take part in clinical trials.
At Arkansas Children’s, we are members of:
A prospective open label, multicenter study to evaluate the feasibility and side effects of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Treatment of cHL in children and young adults – evaluation of pembrolizumab in a subgroup with inadequate early response to frontline chemotherapy.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia.
The purpose of this study is to test the effectiveness of using an investigational agent called DFMO along with etoposide for Neuroblastoma.
This study will evaluate the use of Difluoromethylornithine (DFMO) as a single agent in patients with high risk medulloblastoma after completing therapy as maintenance therapy with the hopes of preventing relapse.
This is an open-label, sequential-arm, Phase 1b/2 clinical trial of bempegaldesleukin in combination with nivolumab in pediatric participants with malignancies that are refractory, relapsed, or participants for whom curative treatments are lacking.
Watch our videos to learn more about how the Cancer and Blood Disorders department at Arkansas Children's is changing children's lives.
Below is a list of community resources that other families have found to be helpful. There are many other programs, agencies, and organizations that we have not listed that may be able to assist your family.